The use of vaccines against SARS-CoV-2, the virus that causes COVID-19, was not linked to an increased risk of disease worsening in people with hereditary angioedema (HAE), according to a small, single-center study from Turkey. The study also found that the viral infection was not always associated with disease worsening…
News
Most people with hereditary angioedema (HAE) can usually predict an impending swelling attack based on early, or prodromal, signs or symptoms, according to an online survey. However, results showed differing behaviors and definitions for “early treatment,” with 60% of the participants taking medications as soon as early symptoms…
An 83-year-old woman suddenly developed angioedema of the airway as a result of neck trauma while being treated with telmisartan, a medication commonly used to lower blood pressure, according to a case report from the U.S. “This case report highlights the rare and often forgotten adverse reaction of angioedema…
Treatment with the experimental under-the-skin injection therapy STAR-0215 reduced the rates of monthly swelling attacks by more than 90% in people with hereditary angioedema (HAE) in a small early clinical trial. That’s according to new data announced by developer Astria Therapeutics, which further showed that HAE attacks…
Long-term daily treatment with Orladeyo (berotralstat) effectively reduced swelling attacks and improved patient-reported outcomes in Japanese adults with hereditary angioedema (HAE), according to data from a Phase 3 clinical trial. Findings were detailed in the study, “Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2…
Pharvaris has started a Phase 3 clinical trial called RAPIDe-3 to test an immediate-release capsule formulation of deucrictibant as an on-demand treatment to manage swelling attacks in hereditary angioedema (HAE). “We hear from the HAE community that rapid onset and complete resolution of angioedema attacks with a single,…
Treatment with tranexamic acid was safe and not linked to a higher risk of worse outcomes in people who developed angioedema after being on angiotensin-converting enzyme inhibitors (ACEIs), a type of blood pressure-lowering medication, a study finds. While initial findings suggested a link between tranexamic acid and greater rates…
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded promising innovative medicine designation to sebetralstat, an experimental oral therapy KalVista Pharmaceuticals is developing as an on-demand treatment to resolve swelling attacks in hereditary angioedema (HAE). The designation is the first step in the Early Access…
Mutations in the CPN1 gene leading to a deficiency in the activity of the carboxypeptidase N (CPN) enzyme were found in four families with hereditary angioedema (HAE), according to a new study from Europe. The team of researchers identified three genetic variants in the CPN1 gene that were associated…
Orladeyo (berotralstat), an oral therapy for preventing swelling attacks in adults and adolescents with hereditary angioedema (HAE), is now available in Italy. The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA), has finalized reimbursement and is recommending Orladeyo as a routine prophylactic (preventive) treatment for people with HAE,…
Recent Posts
- Body stress signals in HAE match those of autoimmune disorder ITP
- Biocryst expands HAE treatment portfolio with Astria acquisition
- When executing a plan, each person must do the right job at the right time
- Blood pressure drug lisinopril causes gut swelling in man, 54, in rare case
- Rare Disease Week is an opportunity to show that rare is not invisible